Heart failure & cardiomyopathiesSecondary analysis

Effects of Dapagliflozin on Heart Failure Hospitalizations According to Severity of Inpatient Course: Insights from DELIVER and DAPA-HF

Eur J Heart FailPublished

  • Secondary analysis of the DELIVER and DAPA-HF randomised trials

Authors' conclusion

Treatment with dapagliflozin consistently reduced HF hospitalizations regardless of severity of inpatient course or LOS.

Study context

Population
Patients with heart failure (HF) across the spectrum of EF (DELIVER and DAPA-HF)1,209 + 799 HF hospitalizations
Comparison
Dapagliflozin vs placebo
Primary endpoint
Total adjudicated HF hospitalizations by complexity (uncomplicated vs complicated: ICU stay, IV vasoactive therapies, ventilation, mechanical fluid removal or mechanical circulatory support) and by LOS

Primary result

As reported in the abstract

Total HF hospitalizations by severity of inpatient course (subgroups)
DapagliflozinRelative risk (95% CI)
uncomplicated, DELIVER
0.67(0.55–0.82)
uncomplicated, DAPA-HF
0.69(0.54–0.87)
complicated, DELIVER
0.82(0.63–1.06)
complicated, DAPA-HF
0.75(0.58–0.97)

Further findings

HF hospitalizations by length of stay (LOS)

ComparisonRR (95% CI)
Dapagliflozin · LOS <5 days, DELIVER0.76 (0.58–0.99)
Dapagliflozin · LOS <5 days, DAPA-HF0.58 (0.42–0.80)
Dapagliflozin · LOS ≥5 days, DELIVER0.71 (0.58–0.86)
Dapagliflozin · LOS ≥5 days, DAPA-HF0.77 (0.62–0.94)

Proportion of HF hospitalizations complicated

DELIVER: uncomplicated 854 (71%), complicated 355 (29%)
DAPA-HF: uncomplicated 453 (57%), complicated 346 (43%)

In-hospital mortality, complicated vs uncomplicated first HF hospitalization

DELIVER: 16.7% vs. 2.3%
P < 0.001
DAPA-HF: 15.1% vs. 3.8%
P < 0.001

Original publication

Effects of Dapagliflozin on Heart Failure Hospitalizations According to Severity of Inpatient Course: Insights from DELIVER and DAPA-HF. Eur J Heart Fail. Published 8 June 2023. doi:10.1002/ejhf.2912

Summarised from the published abstract; every number is checked against it